

Rowan University

Rowan Digital Works

Rowan-Virtua Research Day

25th Annual Research Day

May 6th, 12:00 AM

Multiple Myeloma with Dual Expression of Kappa and Lambda Light Chains

Monica Patel
Rowan University

Akash Patel
Rowan University

Yvette Wang
Rowan University

Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day



Part of the [Hematology Commons](#), [Hemic and Lymphatic Diseases Commons](#), [Neoplasms Commons](#), [Oncology Commons](#), and the [Pathological Conditions, Signs and Symptoms Commons](#)

Let us know how access to this document benefits you - share your thoughts on our [feedback form](#).

Patel, Monica; Patel, Akash; and Wang, Yvette, "Multiple Myeloma with Dual Expression of Kappa and Lambda Light Chains" (2021). *Rowan-Virtua Research Day*. 56.
https://rdw.rowan.edu/stratford_research_day/2021/may6/56

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Rowan-Virtua Research Day by an authorized administrator of Rowan Digital Works.

Introduction

- Multiple myeloma (MM) is a malignancy of plasma cells that accounts for approximately 1 to 2 percent of all cancers and about 17% of all hematologic malignancies.
- Plasma cells normally produce antibodies and provide a defense mechanism for the body to fight infections.
- Antibodies typically consist of two heavy chains (IgG, IgA, IgM, IgD and IgE) and two light chains (kappa and lambda).
- Most cases of MM have malignant plasma cells producing monoclonal (M) proteins, most common being IgG about 52% of the time (1).
- Only about 2% of these myeloma cases were also found to secrete more than one paraprotein and classified as biclonal/biphenotypic plasma cell myeloma (2).
- Here we report a case of a woman who presented with lower back pain that was found to have biphenotypic multiple myeloma with a coexpression of kappa and lambda light chains.





Case Presentation

- 52-year-old African American female was admitted with a chief complaint of lower back pain for a 3-4 months duration.
- PMH: hypertension, peptic ulcer disease and gastroesophageal reflux disease
- Labs were significant for elevated **serum creatinine of 6.13** and serum **calcium of 12.5, hemoglobin of 8.4.**
- Renal ultrasound showed no hydronephrosis or renal calculi, **increased bilateral cortical echogenicity**, indicative of some degree of underlying chronic kidney disease.
- SPEP showed **positive free lambda (23993), positive free kappa light chain (43.2)** normal IgG and IgA ratio, low IgM (25).
- Urinalysis was significant of 100+ protein and **urine protein to creatinine ratio consistent with 11.97 grams**
- Bone Survey showed heterogenous appearance of the right humerus with scattered ill-defined lytic lesions. Possible ill-defined lytic lesions are seen at the proximal left tibia. There was a **lytic lesion** at the proximal left radius.
- Treated with dexamethasone for multiple myeloma and pamidronic acid for hypercalcemia with a resolution of serum calcium level to 8.5mg/dL.
- Patient also **required hemodialysis** for her acute renal failure.

Figures

- Figure 1 and 2: Renal biopsy with tubular atrophy and interstitial fibrosis
- Figure 3: Immunofluorescence staining for Kappa
- Figure 4: Immunofluorescence staining for Lambda

Pathology



Discussion

- In older patients presenting with lower back pain and acute renal failure, the diagnosis of multiple myeloma should be on the differential
- MM the leading cause of malignancy induced ESRD requiring dialysis.
- The kidneys metabolizes light chain proteins but Ig and heavy chains do not pass through the glomerular filtration barriers.
- Light chains that are filtered are reabsorbed by proximal tubular cells and catabolized by lysozymal enzymes, normally this process is very efficient.
- When the burden of light chains exceeds the absorption capacity of the tubules, light chains spill into the urine (3).
- Free light chains enter proximal tubule cells and trigger apoptosis and inflammation (4).
- Free light chains bind to Tamm-Horsfall protein to form casts which result in tubular atrophy, interstitial inflammation and fibrosis leading to renal failure

Treatment Options

- Early diagnosis and initiation of therapy is the best treatment
- MM patients requiring dialysis have a higher mortality than other causes of ESRD with a greater than 85% mortality within 2 years (5).
- Pharmacologic Therapy-Bortezomib-based therapy, especially triple drug therapy (thalidomide, dexamethasone and bortezomib) has improved survival of patients with mild to moderately reduced kidney function and those requiring dialysis.
- Plasmapheresis-removing light chains from plasma leading to less being filtered by the kidney and causing less damage. Studies have shown mixed results with no clear evidence of mortality benefit.
- Stem cell transplantation (SCT)-potentially curative for a small number of patients. Interesting renal failure may prevent patient's them from qualifying for SCT, one of the disease's most effective treatments (6).
- Kidney transplant-clear curative option for patients with MM and ESRD

References

- Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016;34(13):1544-1557. doi:10.1200/JCO.2015.65.0044
- Jiwani S, Bornhost J, Alapat D. Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains. Int J Clin Exp Pathol. 2015;8(7):8536-8544. Published 2015 Jul 1.
- Fang, Leslie S. Light Chain Nephropathy. Kidney Inter. 1985; 27:582-592
- Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2011;8(1):43-51. Published 2011 Nov 1. doi:10.1038/nrneph.2011.168
- Reule S, Sexton DJ, Solid CA, Chen SC, Foley RN. ESRD due to Multiple Myeloma in the United States, 2001-2010. J Am Soc Nephrol. 2016;27(5):1487-1494. doi:10.1681/ASN.2014090876
- Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013;8(11):2007-2017. doi:10.2215/CJN.12231212